Oral paricalcitol: expanding therapeutic options for pediatric chronic kidney disease patients

Abstract

The complex pathophysiology of progressive chronic kidney disease (CKD) and the development of mineral and bone disorder, abbreviated as CKD-MBD, is of vital importance to a pediatric patient. Paricalcitol, the 19 nor-1,25(OH)2D2 analogue was shown to be effective and safe in the treatment of secondary hyperparathyroidism (SHPT) in adults almost two decades… (More)
DOI: 10.1007/s00467-017-3675-7

Topics

1 Figure or Table

Slides referencing similar topics